SPCEO1 wrote: In today's parlance, anytime CYDY is mentioned, it "triggers" me! I now need to retreat to my safe room since you mentioned those four letters! To be fair, CYDY's valuation also tells you something about the lunatics who are willing to invest in CYDY given that fact pattern. But if CYDY can find that many lunatics to buy the nonsense they are selling, how hard can it be for TH to find some more sensible investors to buy into the legit opportunities they are selling.
The problem TH has had is mostly one of no one paying any attention to them. The story on cancer and NASH keeps getting better but the analysts following the company still keep falling away and the retail investor community has never been engaged. The conference call they had on the move to general NASH last September was about as well done as any of us could have hoped for, but no one but us were listening to it, so it had no impact.
If they had a plan to engage the investment community, and I am sure they did, it has been a epic failure. And that failure, particularly during a bull market bonanza where even a fraud like CYDY can find people to prop up its stock price, has been extreme. I would even say that failure has been extremely extreme. It has been just off the charts bad.
Which led to us justly hammering the leaddership of TH when the ultimate price of that extemely extreme failure really hit its peak absurdity in the OO.
While it is the BOD's fault this was allowed to get to this ugly point, we should at least credit them for speaking with Wino and committing to make changes, some of which are already underway. The bull market might soon be in the rear view mirror (and CYDY's executives may find themselves in serious legal jeopardy), so that rare opportunity for unusally large profits in TH may never pan out for us, but if TH can make just one of their two R&D programs work while simultaneously engaging properly with the investment community, the stock should eventually trade much, much higher and help atone for the past mis-steps.
The BOD just needs to stop allowing stupid stuff to happen. The capital markets person who is currently missing from this board has been shown to be a huge hole that has had disastrous consequences for the stock. I am glad they have committed to fix that. Before any major decision, they should ask the question "Would Warren Buffett make this move?" That alone would likely have steered them away from decisions like the OO and the imcomprehensibly long period of blowing up analysts earnings models due to a lack of guidance and thereby destroying the company's credibility with the investment community. Yes, the analysts have their own issues too but TH needs to manage that by steering the analysts with guidance. Misleading the investment community like they did with the Q4 to Q1 sales drop-off costs way more in the long run than telling the truth about the sales situation.
I promise to come out of my safe room sometime today to indicate how I will vote the shares we control. Thanks to all of you for the excellent contributions that have been made on that subject here as they have been very helpful as I considered this unfortunate situation.
jeffm34 wrote: TH would have to be trading at over $20 cnd to equal the market cap of CYDY. Cytodyne has 1 drug candidate in trials which if successful they hope will compete with Trogarzo. They already gave away 50% of their potential sales in a commercialization deal. The Covid trials are just a PR stunt. They have dozens of class action lawsuits pending against them. Last year end they lost over $100M and had zero revenue with about 15M cash.
TH already has 2 drugs producing sales, an oncology program with a massive potential market and a phase 3 NASH program. Yet we trade at 1/5 of what CYDY trades at. That tells you everything you need about the ability of our current BOD and management to get a real story out to the right people.